Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations

Hanako Kohama,1 Takeshi Ide,1 Kazuro Ikawa,2 Norifumi Morikawa,2 Shinichi Nishi1 1Division of Intensive Care Unit, Hyogo College of Medicine, Nishinomiya, 2Department of Clinical Pharmacotherapy, Hiroshima University, Hiroshima, Japan Background: Tazobactam/piperacillin (TAZ/PIPC), which is often co...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kohama H, Ide T, Ikawa K, Morikawa N, Nishi S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Continuous renal replacement therapy tazobactam/piperacillin pharmacokinetics dosage considerations Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/3f1737d6e2a64a4c9feaf574a2aab771
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3f1737d6e2a64a4c9feaf574a2aab771
record_format	dspace
spelling	oai:doaj.org-article:3f1737d6e2a64a4c9feaf574a2aab7712021-12-02T00:31:03ZPharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations1179-1438https://doaj.org/article/3f1737d6e2a64a4c9feaf574a2aab7712017-02-01T00:00:00Zhttps://www.dovepress.com/pharmacokinetics-and-outcome-of-tazobactampiperacillin-in-japanese-pat-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Hanako Kohama,1 Takeshi Ide,1 Kazuro Ikawa,2 Norifumi Morikawa,2 Shinichi Nishi1 1Division of Intensive Care Unit, Hyogo College of Medicine, Nishinomiya, 2Department of Clinical Pharmacotherapy, Hiroshima University, Hiroshima, Japan Background: Tazobactam/piperacillin (TAZ/PIPC), which is often combined with continuous renal replacement therapy (CRRT), induces renal excretion and is thought to have a high component removal rate for blood purification. CRRT procedures vary depending on the country, region, and institution. It is not clear whether the dose of TAZ/PIPC for use in Japan can be determined based on studies conducted in other countries. Therefore, in this study, we examined the suitability of recommended dose in Japan. Methods: The study subjects consisted of 10 patients who received TAZ/PIPC during CRRT in the intensive care unit of Hyogo College of Medicine, Nishinomiya, Japan. We used a one-compartment model to characterize and parameterize the pharmacokinetics of TAZ/PIPC because their blood levels were eliminated monoexponentially. Results: Compared with the data of healthy adults, the half-lives (t1/2) of both PIPC and TAZ were prolonged while their clearance rates decreased. Conclusion: For the continuous hemodiafiltration procedure adopted in Japan, we concluded that the dose and frequency were appropriate because the patients who received PIPC/TAZ 2.25 g twice a day during continuous hemodiafiltration maintained appropriate blood levels of both PIPC and TAZ. Keywords: hemodiafiltration, antibiotics, dosage regimenKohama HIde TIkawa KMorikawa NNishi SDove Medical PressarticleContinuous renal replacement therapytazobactam/piperacillinpharmacokineticsdosage considerationsTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 9, Pp 39-44 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Continuous renal replacement therapy tazobactam/piperacillin pharmacokinetics dosage considerations Therapeutics. Pharmacology RM1-950
spellingShingle	Continuous renal replacement therapy tazobactam/piperacillin pharmacokinetics dosage considerations Therapeutics. Pharmacology RM1-950 Kohama H Ide T Ikawa K Morikawa N Nishi S Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations
description	Hanako Kohama,1 Takeshi Ide,1 Kazuro Ikawa,2 Norifumi Morikawa,2 Shinichi Nishi1 1Division of Intensive Care Unit, Hyogo College of Medicine, Nishinomiya, 2Department of Clinical Pharmacotherapy, Hiroshima University, Hiroshima, Japan Background: Tazobactam/piperacillin (TAZ/PIPC), which is often combined with continuous renal replacement therapy (CRRT), induces renal excretion and is thought to have a high component removal rate for blood purification. CRRT procedures vary depending on the country, region, and institution. It is not clear whether the dose of TAZ/PIPC for use in Japan can be determined based on studies conducted in other countries. Therefore, in this study, we examined the suitability of recommended dose in Japan. Methods: The study subjects consisted of 10 patients who received TAZ/PIPC during CRRT in the intensive care unit of Hyogo College of Medicine, Nishinomiya, Japan. We used a one-compartment model to characterize and parameterize the pharmacokinetics of TAZ/PIPC because their blood levels were eliminated monoexponentially. Results: Compared with the data of healthy adults, the half-lives (t1/2) of both PIPC and TAZ were prolonged while their clearance rates decreased. Conclusion: For the continuous hemodiafiltration procedure adopted in Japan, we concluded that the dose and frequency were appropriate because the patients who received PIPC/TAZ 2.25 g twice a day during continuous hemodiafiltration maintained appropriate blood levels of both PIPC and TAZ. Keywords: hemodiafiltration, antibiotics, dosage regimen
format	article
author	Kohama H Ide T Ikawa K Morikawa N Nishi S
author_facet	Kohama H Ide T Ikawa K Morikawa N Nishi S
author_sort	Kohama H
title	Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations
title_short	Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations
title_full	Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations
title_fullStr	Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations
title_full_unstemmed	Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations
title_sort	pharmacokinetics and outcome of tazobactam/piperacillin in japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/3f1737d6e2a64a4c9feaf574a2aab771
work_keys_str_mv	AT kohamah pharmacokineticsandoutcomeoftazobactampiperacillininjapanesepatientsundergoinglowflowcontinuousrenalreplacementtherapydosageconsiderations AT idet pharmacokineticsandoutcomeoftazobactampiperacillininjapanesepatientsundergoinglowflowcontinuousrenalreplacementtherapydosageconsiderations AT ikawak pharmacokineticsandoutcomeoftazobactampiperacillininjapanesepatientsundergoinglowflowcontinuousrenalreplacementtherapydosageconsiderations AT morikawan pharmacokineticsandoutcomeoftazobactampiperacillininjapanesepatientsundergoinglowflowcontinuousrenalreplacementtherapydosageconsiderations AT nishis pharmacokineticsandoutcomeoftazobactampiperacillininjapanesepatientsundergoinglowflowcontinuousrenalreplacementtherapydosageconsiderations
_version_	1718403670850142208

Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations

Ejemplares similares